A look at Beam Therapeutics Inc’s (BEAM) recent performance gives investors their first glimpse of hope.

Beam Therapeutics Inc (NASDAQ: BEAM) kicked off on Monday, down -3.63% from the previous trading day, before settling in for the closing price of $25.65. Over the past 52 weeks, BEAM has traded in a range of $16.95-$49.50.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 43297.50%. While this was happening, its average annual earnings per share was recorded -173.40%. With a float of $71.60 million, this company’s outstanding shares have now reached $81.63 million.

Considering the fact that the conglomerate employs 436 people, you should pay attention to its efficiency factor.

Beam Therapeutics Inc (BEAM) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 13.13%, while institutional ownership is 81.40%. The most recent insider transaction that took place on Jul 02 ’24, was worth 17,167. In this transaction Chief Medical Officer of this company sold 748 shares at a rate of $22.95, taking the stock ownership to the 68,805 shares. Before that another transaction happened on Jul 01 ’24, when Company’s Chief Medical Officer sold 502 for $23.76, making the entire transaction worth $11,928. This insider now owns 69,553 shares in total.

Beam Therapeutics Inc (BEAM) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around -173.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.

Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators

Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.78.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.67 in one year’s time.

Technical Analysis of Beam Therapeutics Inc (BEAM)

Compared to the last year’s volume of 1.27 million, its volume of 1.04 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 60.00%. Additionally, its Average True Range was 1.37.

During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 28.36%, which indicates a significant decrease from 41.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.48% in the past 14 days, which was lower than the 61.06% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $26.26, while its 200-day Moving Average is $27.29. Nevertheless, the first resistance level for the watch stands at $25.54 in the near term. At $26.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $26.90. If the price goes on to break the first support level at $24.18, it is likely to go to the next support level at $23.65. Should the price break the second support level, the third support level stands at $22.83.

Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats

The company with the Market Capitalisation of 2.04 billion has total of 82,311K Shares Outstanding. Its annual sales at the moment are 377,710 K in contrast with the sum of -132,530 K annual income. Company’s last quarter sales were recorded 11,770 K and last quarter income was -91,050 K.